Target intelligence / Profile preview

ATP-dependent RNA helicase DDX39A (DDX39A)

Target
DDX39A
Molecular classification
Enzyme (RNA helicase; DEAD box family), Helicase superfamily 2 (SF2), RNA-binding protein, Splicing factor
01

Overview

ATP-dependent RNA helicase DDX39A is a member of the DEAD box protein family and acts as an RNA-dependent ATPase within helicase superfamily 2. It participates in essential aspects of RNA metabolism, including mRNA nuclear export, spliceosomal snRNA export, and pre-mRNA alternative splicing[1][3][5]. DDX39A works as a molecular motor to remodel RNA-protein complexes, driven by ATP hydrolysis, thereby influencing gene expression, RNA stability, and cellular homeostasis. Its activity is critical for transcriptome regulation, and its paralog DDX39B shares some overlapping but distinct functions. DDX39A also modulates innate immune responses by controlling the retention and export of antiviral transcripts, and has been implicated in cancer, infection, and possibly other disease processes[2][3][4][5]. Clinical targeting of DDX39A faces safety concerns due to its ubiquitous and essential cellular roles.

Other names
DEAD box protein 39URH49BAT1BAT1LDDX39DDXLNuclear RNA helicase URH49UAP56-related helicase, 49 kDaDEAD (Asp-Glu-Ala-Asp) box polypeptide 39ADECD variant of DEAD box family
02

Mechanism of action

Hypothetical inhibitors would work by blocking ATP binding or hydrolysis, thus interrupting helicase activity and RNA metabolism. Experimental modulation may influence mRNA export, splicing, or innate immunity signaling[1][2][5].

03

Biological functions

mRNA export from nucleusAlternative splicingSpliceosomal small nuclear RNA (snRNA) exportRNA metabolism (including unwinding RNA duplexes; RNA-protein complex remodeling)Negative regulation of type I interferon productionCellular growth and divisionEmbryogenesis and spermatogenesis (proposed roles in developmental processes)
04

Disease associations

Cancer (implicated in GI stromal tumor prognosis; present in some cancer pathways)Infection (relevant to Chikungunya, Flinders Island Spotted Fever, and antiviral activity)Inflammation (modulation of interferon responses)Other (RNA virus infection and innate immunity)
05

Safety considerations

Potential challenges include off-target inhibition of essential RNA metabolism, leading to cellular toxicity; dual inhibition with DDX39B causes loss of cell viability[1].Risks include global impairment of splicing or mRNA export, affecting cell survival and homeostasis.Because DDX39A is widely expressed and critical for basic RNA processing, drug targeting may risk systemic side effects if not highly selective.
06

Interacting drugs

Currently, no specific approved drugs directly target DDX39A. Its role in antiviral defenses and cancer biology suggests it may be explored for inhibitor development, but no named drugs have been validated in clinical or preclinical human use.
07

Biomarkers

DDX39A expression may serve as a biomarker for cancer prognosis (e.g., gastrointestinal stromal tumors)[3].Potentially as a marker for altered splicing events or interferon response modulation, but not currently established in clinical guidelines.

Beyond the preview

Go deeper on ATP-dependent RNA helicase DDX39A (DDX39A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-dependent RNA helicase DDX39A (DDX39A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call